Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma.
Department of Dermatology, Fukushima Medical University, Fukushima 960-1295, Japan.
Natsuko
N
Matsumura
Mikio
M
Ohtsuka
Nobuyuki
N
Kikuchi
Toshiyuki
T
Yamamoto
D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001706:Biopsy; D018450:Disease Progression; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced / Q000175:diagnosis; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D000077594:Nivolumab; D011565:Psoriasis / Q000139:chemically induced* / Q000175:diagnosis; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077594:Nivolumab